You could sell some or all of your Ocugen shares and buy long-term call options on the stock. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. Ocugen. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. The statistics support having long-term exposure to this asset class. To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Considering Bharats reputation for world-class R&D and manufacturing capabilities in vaccines and bio-therapeutics, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a suitable partner.. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). Custom BMW. Keith Speights has no position in any of the stocks mentioned. I will just say this on Ocugen: Theres a reason it trades for sub-$1 after hitting resistance near $180 in 2018. In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. ET on Friday. All rights reserved. However, when that occurred, Ocugen stock lost most of its value. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. Like other life sciences companies involved in Covid-19 vaccine. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. The Ocugen deal is a way to salvage some limited value. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. The point is, the risk/reward of owning something like Ocugen is simply not worth it vs. having even basic equity exposure. 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. I will concede this: The one great thing about the stock market is there is a style for everyone. Guys, theres no revenue here! Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. The average Ocugen stock price for the last 52 weeks is 2.10. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Sign up below to get this incredible offer! Axsome Therapeutics (NASDAQ:AXSM) had an equity value below $75 million in March 2017; its now worth over $3 billion after rising over 1,000% last year. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. (See OCGN stock analysis on TipRanks). It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. Maybe. As of this writing, Vince Martin has no positions in any securities mentioned. Written by Histogenics shareholders then received about 14% of the company, according to the merger prospectus. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The latest closing stock price for Ocugen as of March 03, 2023 is. That's right -- they think these 10 stocks are even better buys. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. MALVERN, Pa., May 29, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO International Convention, taking place June 4-7, 2018, in Boston. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). Some investors had set their hopes on the FDA being more lenient with pediatric use of Covaxin. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion 0.90% SPY 0.59% QQQ 0.60% TSLA 6.12% SI 60.35% CRM 11.51% RIVN 0.32% ARKK 0.96% RLY.X 56.44% PLUG 6.72% V 0.22% CDIO 13.87% RETA 5.92% More Advertisement 3rd Party Ad. Copyright Type a symbol or company name. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. If Ocugen goes up, you can still profit. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. Keith Speights owns shares of Pfizer. It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. 1125 N. Charles St, Baltimore, MD 21201. If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. OCGN does not even appear to have an apparent reason to exist. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. The Motley Fool recommends Moderna Inc. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Objective investors could have clearly seen then that there actually were significant reasons to be concerned. With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell Amryt Pharma releases Q-2 how to setup copy trading labrador gold stock that show strong revenue growth as The first split for NKE took place on October 08, Below, we'll pit these two dominant consumer-discretionary giants against each other, with an eye toward long-term . 1125 N. Charles St, Baltimore, MD 21201. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. As of this writing, Matt did not hold a position in any of theaforementioned securities. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Our 3 Top Picks. Type a symbol or company name. These options will be cheaper than owning the stock itself. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. The Ocugen 52-week high stock price is 4.03, which is 328.7% above the current share price. This decision. Unfortunately for longs, OCGN is much closer to the worst of conditions. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. The Motley Fool has a disclosure policy. *ALL INFO ABOUT THE BIKE AND GEAR USED DOWN BELOW**If not listed it's left stock*BIKE: 2018, BMW R NINET SCRAMBLER.EXHAUST: Akrapovic Headers, Uni. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. But if they do, Ocugen stock at the least looks like an intriguing bet. The Ocugen 52-week low stock price is 0.93, which is 1.1% below the current share price. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. The S&P 500 has rallied 52.9% from the March low to its highs on August 6. It has real management. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. It is very important to do your own analysis before making any investment. By the beginning of March, the stock was still trading at 45 cents as news of the coronavirus spreading in China prompted concerns about a U.S. pandemic. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. The company is led by CEO and Co-founder, Shankar Musunuri, and entered into the public equity market in 2019 via. I am all for a good opportunity, but I dont know why some investors insist on penny stocks. You canfollow Will on Twitterat @HealyWriting. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Investors need to understand the risk profile here. 1125 N. Charles St, Baltimore, MD 21201. It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. That's right -- they think these 10 stocks are even better buys. Pricing likely would be favorable, given the lack of alternative treatments. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. Conditions have only become worse since that time. The CanSinoBio partnership does help, but Ocugen still has a long way to go with OCU300. How can we possibly evaluate a stock on a fundamental basis with that being reality? Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. quotes delayed at least 15 minutes, all others at least 20 minutes. Related Link: If You Invested $1,000 In Moderna Stock One Year Ago, Here's How Much You'd Have Now. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. The potential synergies of such a union do not seem clear. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Typically, I care little about financials with biotechs. Keith Speights has no position in any of the stocks mentioned. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. Making the world smarter, happier, and richer. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. Type a symbol or company name. The second is that the balance sheet still needs some help. Type a symbol or company name. The Motley Fool->. Investing is always a game of balancing risk and reward. The OCGN stock forecast 2022 outlook suggests that Ocugen's stock may struggle in the short term. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. Please check your download folder. Part of the proceeds will be used to support its partnership with Bharat. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." If they have solid financials, but their trials continually fail, they will likely not succeed. And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. It has no treatments to offer the market. Keith Speights for On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. Thats why we give you a wide range of Options on stocks, indices, commodities and FX. To be sure, current cash isnt enough. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. The odds of Ocugen stock winding up at zero are material. Not an offer or recommendation by Stocktwits. *Average returns of all recommendations since inception. Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. That's not going to happen now. Long-term debt of $1.6 million is not a back-breaker either. It brings in no revenue. Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. These symbols will be available throughout the site during your session. Nasdaq Even though Ocugen did raise $25 million in a private placement, the story behind OCU300 clearly was not enough to support an initial public offering on its own. For now, the biggest near-term hope for Covaxin may be that Canada or another developed economy will buy the vaccine to share with developing nations. The Motley Fool has no position in any of the stocks mentioned. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. The Motley Fool has a disclosure policy. Copyright 2023 InvestorPlace Media, LLC. Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. If it goes down, your loss won't be as great as it would be if you held onto all of your shares. The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Investors should worry about companies with no revenue even under the best of circumstances. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. It means that institutional investors focused on the sector largely have passed on the pipeline. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. Thats one of the best rallies weve seen in that amount of time (95 trading sessions, 136 days). The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. Create your Watchlist to save your favorite quotes on Nasdaq.com. The Nasdaq has been even more impressive, rallying 67.7% in the same time frame and hitting new all-time highs in the process.
Singapore Airlines Newsroom,
Not Rejected Just Unwanted Book Series,
Why Naphthalene Is Less Aromatic Than Benzene,
Articles O